Please assess the completion status of the following clinical trial:

Trial Title: Idebenone to Treat Friedreich's Ataxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Diagnosis of FA with confirmed FRDA mutations.~Age from nine up to but not over eighteen years.~Weight between 30 to 80 kilograms.~Ambulatory (assistance devices permitted).~Willing to participate in all aspects of trial design and follow-up.~All subjects agree and commit to the use of 2 reliable methods of birth control for the duration of the study if sexually active.~Neurologically symptomatic.~No exposure to idebenone, coenzyme Q10, or other dietary supplements for a period of at least one month before enrollment in the study.~EXCLUSION CRITERIA:~History of a hypersensitivity reaction to idebenone or coenzyme Q10.~Pregnant or lactating women. All women of child-bearing potential must have negative serum pregnancy prior to the medication phase of the study. If a minor has a positive pregnancy test, we will inform her but not inform her parents unless we are asked to by the minor.~Platelet count, white blood cell count or hemoglobin below the lower limit of normal.~Alkaline phosphatase, SGOT, or SGPT greater than 1.5 times the upper limit of normal. Bilirubin greater than 1.5 g/dl.~Creatinine greater than 1.5 times the upper limit of normal based upon the pediatric reference range provided by the testing laboratory.~Clinically significant medical disease that, in the judgment of the investigators, would expose the patient to undue risk of harm or prevent the patient from completing the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).